Results 111 to 120 of about 8,268,208 (290)

Generation and application of recombinant antibody fragments for prostate cancer detection. [PDF]

, 2010
Prostate cancer (PCa) is the most prevalent adenocarcinoma and the second highest cause of cancer-related deaths in men. Early diagnosis is required to identify the development of PCa to reduce the risk of the disease metastasising to different regions ...
Hayes, Conor
core   +1 more source

Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth

, 2006
PURPOSE: The antiproliferative effects of pharmacological agents used for androgen ablative therapy in prostate cancer, including goserelin, bicalutamide and cyproterone acetate (Fluka Chemie, Buchs, Switzerland), were tested in vitro.
Peternac, Daniel, Studer, Urs E, Klima, Irena, Cecchini, Marco G, Thalmann, George N, Studer, Urs, Studer, Urs E., Studer UE, Cecchini, Marco G., Cecchini MG, Thalmann GN, Thalmann, George N., Peternac D, Klima I, Thalmann, George   +14 more
core   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source

Prostate-specific antigen.

The Western journal of medicine, 1992
The Scientific Board of the California Medical Association presents the following inventory of items of progress in urology. Each item, in the judgment of a panel of knowledgeable physicians, has recently become reasonably firmly established, both as to scientific fact and important clinical significance.
openaire   +3 more sources

Molecular expression and immunotherapeutic potential of the novel tumour associated antigen T21 [PDF]

, 2013
The application of immunotherapeutic approaches to target tumour cells by harnessing the body’s most important defence the immune system, could provide opportunities to oppose cancer.
Malhi, S.K.
core  

Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer

Advanced Science, EarlyView.
The schematic diagram depicts a compartmentalized anti‐ferroptotic defense mechanism mediated by GSTA4. GSTA4 is upregulated and localizes to the cytoplasm in ENZR cells, where it detoxifies 4‐HNE via a non‐canonical GSH‐dependent pathway. Under oxidative stress, GSTA4 translocates to mitochondria, interacts with PGAM5, and blocks Drp1 Ser637 ...
Yong Luo, Wei Zhuang, Zean Li, Yiming Lai, Yongyi Ou, Dongquan Li, Shanhe Huang, Tianlong Luo, Jintao Hu, Bingliang Chen, Jianhan Fu, Tao Zhuo, Hankun Jiang, Yin Lu, Hai Huang, Kewei Xu, Shengmeng Peng, Qing Yuan   +17 more
wiley   +1 more source

Degrading GPX4 via Biomimetic Nanoparticle‐Mediated In Situ Synthesis of Deep‐Learning‐Designed Binder‐Degron Chimeras for Prostate Cancer Therapy

Advanced Science, EarlyView.
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang, Ye An, Na Zeng, Mei‐Cheng Liu, Jian‐Xuan Sun, Xi Gong, Jin‐Zhou Xu, Shao‐Gang Wang, Qi‐Dong Xia   +8 more
wiley   +1 more source

Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil

BMC Urology
Background Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes.
Juan Manuel Palacios, Pratiksha Kapse, Vanessa Cortes, Marcio Augusto Averbeck, Alberto Budia Alba, Suryakant Somvanshi, Danilo Souza Lima da Costa Cruz, Fiona Pereira   +7 more
doaj   +1 more source

Prostate‐specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death

, 2006
BACKGROUND. The nadir prostate-specific antigen (PSA) at 1 year (nPSA12) was investigated as an early estimate of biochemical and clinical outcome after radiotherapy (RT) alone for localized prostate cancer.
Alcántara Carrió, María Del Pino, Pollack, Alan, Hanlon, Alexandra, Horwitz, Eric, Buyyounouski, Mark   +4 more
core   +1 more source

NCOA4 Accelerates Abdominal Aortic Aneurysm Formation by Regulating Macrophage Activation and Ferroptosis via STAT1–CH25H Axis

Advanced Science, EarlyView.
Under pathological stimulation, NCOA4 in macrophages interacts with STAT1 to promote CH25H transcription. The subsequent increase in 25‐HC production activates macrophages, triggers inflammatory responses and ferroptosis, and accelerates the progression of AAA.
Zhinan Wu, Yuxuan Qian, Wenyi Xu, Fei Liao, Xueliang Liu, Xiao Kuang, Guqing Luo, Xinjie He, Lixian Jiang, Song Ding   +9 more
wiley   +1 more source